Drug Profile
Research programme: anticancer therapeutics - i2 Pharmaceuticals
Latest Information Update: 24 Aug 2023
Price :
$50
*
At a glance
- Originator i2 Pharmaceuticals
- Developer i2 Pharmaceuticals; Sea Lane Biotechnologies
- Class Antineoplastics; Bispecific antibodies; Immunoconjugates
- Mechanism of Action ERBB-3 receptor modulators; TRAIL receptor 1 agonists; TRAIL receptor 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer